BSX Relative Valuation
BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BSX is overvalued; if below, it's undervalued.
Historical Valuation
Boston Scientific Corp (BSX) is now in the Fair zone, suggesting that its current forward PE ratio of 29.74 is considered Fairly compared with the five-year average of 27.05. The fair price of Boston Scientific Corp (BSX) is between 83.78 to 107.02 according to relative valuation methord.
Relative Value
Fair Zone
83.78-107.02
Current Price：98.57
Fair
29.48
PE
1Y
3Y
5Y
Trailing
Forward
23.57
EV/EBITDA
Boston Scientific Corp. (BSX) has a current EV/EBITDA of 23.57. The 5-year average EV/EBITDA is 21.41. The thresholds are as follows: Strongly Undervalued below 14.20, Undervalued between 14.20 and 17.80, Fairly Valued between 25.01 and 17.80, Overvalued between 25.01 and 28.61, and Strongly Overvalued above 28.61. The current Forward EV/EBITDA of 23.57 falls within the Historic Trend Line -Fairly Valued range.
25.72
EV/EBIT
Boston Scientific Corp. (BSX) has a current EV/EBIT of 25.72. The 5-year average EV/EBIT is 23.38. The thresholds are as follows: Strongly Undervalued below 16.17, Undervalued between 16.17 and 19.77, Fairly Valued between 26.98 and 19.77, Overvalued between 26.98 and 30.58, and Strongly Overvalued above 30.58. The current Forward EV/EBIT of 25.72 falls within the Historic Trend Line -Fairly Valued range.
6.73
PS
Boston Scientific Corp. (BSX) has a current PS of 6.73. The 5-year average PS is 5.65. The thresholds are as follows: Strongly Undervalued below 3.35, Undervalued between 3.35 and 4.50, Fairly Valued between 6.81 and 4.50, Overvalued between 6.81 and 7.96, and Strongly Overvalued above 7.96. The current Forward PS of 6.73 falls within the Historic Trend Line -Fairly Valued range.
29.97
P/OCF
Boston Scientific Corp. (BSX) has a current P/OCF of 29.97. The 5-year average P/OCF is 28.90. The thresholds are as follows: Strongly Undervalued below 17.11, Undervalued between 17.11 and 23.00, Fairly Valued between 34.79 and 23.00, Overvalued between 34.79 and 40.68, and Strongly Overvalued above 40.68. The current Forward P/OCF of 29.97 falls within the Historic Trend Line -Fairly Valued range.
47.23
P/FCF
Boston Scientific Corp. (BSX) has a current P/FCF of 47.23. The 5-year average P/FCF is 37.29. The thresholds are as follows: Strongly Undervalued below 19.44, Undervalued between 19.44 and 28.37, Fairly Valued between 46.21 and 28.37, Overvalued between 46.21 and 55.14, and Strongly Overvalued above 55.14. The current Forward P/FCF of 47.23 falls within the Overvalued range.
Boston Scientific Corp (BSX) has a current Price-to-Book (P/B) ratio of 6.25. Compared to its 3-year average P/B ratio of 5.38 , the current P/B ratio is approximately 16.15% higher. Relative to its 5-year average P/B ratio of 4.66, the current P/B ratio is about 34.10% higher. Boston Scientific Corp (BSX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.76%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.87% , the current FCF yield is about -100.00% lower.
6.19
P/B
Median3y
5.38
Median5y
4.66
2.62
FCF Yield
Median3y
1.76
Median5y
1.87
Competitors Valuation Multiple
The average P/S ratio for BSX's competitors is , providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 20.34%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BSX increased by 9.40% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 11.12 to 14.91.
The secondary factor is the Revenue Growth, contributed 20.34%to the performance.
Overall, the performance of BSX in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Boston Scientific Corp (BSX) currently overvalued or undervalued?
What is Boston Scientific Corp (BSX) fair value?
How does BSX's valuation metrics compare to the industry average?
What is the current P/B ratio for Boston Scientific Corp (BSX) as of Dec 05 2025?
What is the current FCF Yield for Boston Scientific Corp (BSX) as of Dec 05 2025?
What is the current Forward P/E ratio for Boston Scientific Corp (BSX) as of Dec 05 2025?